Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study developed a questionnaire based on Andersen’s behavioral model to explore psychological well-being and mental health help-seeking behaviors among alopecia areata patients from underserved communities, aiming to better understand factors influencing their mental healthcare utilization.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

This source explains that unlike genetic hormonal alopecia, alopecia areata is associated with inflammatory factors and may also involve psychological and genetic contributions.

This study reports promising preliminary trends in the safety and efficacy of a botanical drug candidate for pediatric alopecia areata, but conclusive results are not yet available.

This review reports that three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—have gained FDA approval for treating alopecia areata due to their demonstrated efficacy in fostering hair regrowth in clinical trials.

This document provides supplementary materials for a study on the efficacy and safety of a topical siRNA-based formulation targeting DKK-1 in treating androgenetic alopecia, but reports no new findings.

This study found a significant association between androgenetic alopecia and both hypertension and diabetes mellitus among patients at UMI Faculty of Medicine, RS Ibnu Sina, and Menara UMI Makassar.

This study examined the current clinical practices for diagnosing and managing alopecia areata in Poland, finding that patient care is inadequate and falls short in using validated severity tools and providing access to advanced therapies despite the availability of new medications like Janus kinase inhibitors.

This study found that the Alopecia Areata Symptom Impact Scale (AASIS) is a better tool than the Alopecia Areata Quality of Life Index (AA-QLI) for assessing patient-reported outcomes in alopecia areata.

This study found that patients with alopecia areata have significantly higher medication adherence than those with atopic dermatitis, potentially due to the stability and controllability of alopecia areata symptoms.

A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.

This study assessed the psychosocial impact and disease burden of alopecia areata among adolescents and adults in Australia, finding substantial impacts on physical, emotional, and quality of life overall, with greater disease burden in patients experiencing more extensive hair loss.

This case report highlights an atypical presentation of acrodermatitis enteropathica in an 18-year-old male, exhibiting symptoms like erythrokeratoderma variabilis with a positive response to high-dose oral zinc, underscoring the importance of considering zinc deficiency in unusual skin conditions.

This study concluded that combining systemic cyclosporine A with low-dose corticosteroids effectively treats severe alopecia areata while maintaining safe cyclosporine A levels in the blood.

This study investigated genetic and phenotypic characteristics of androgen insensitivity syndrome in individuals with a 46,XY karyotype, documenting a range from complete to partial insensitivity.

This study revealed that tofacitinib may inhibit CD8⁺ T cell infiltration in alopecia areata by modulating the linoleic acid metabolism-Mg²⁺ pathway, providing new insights for potential treatments and diagnosis.

This report describes a rare case of epidermolysis bullosa acquisita in a child developing during therapy with squaric acid dibutyl ester for alopecia areata, suggesting a possible link between the medication and disease onset.

This study developed a smart PVA-TPE/HA-AMP/SF/ALG wound dressing that shows promise in infected wound healing by providing bacterial resistance, promoting cell proliferation, and modulating inflammation through various signaling pathways, potentially reducing scar formation.

This case study reports that abrocitinib therapy led to clinical remission of alopecia universalis in a patient with a history of drug-induced DRESS, suggesting its potential as a treatment option.

JAK inhibitors help regrow eyebrow and eyelash hair and improve anxiety and depression in some alopecia areata patients.

This literature review on JAK inhibitors reports that ocular side effects are rare but could be significant, with an inability to establish a causal link. Clinicians are advised to monitor such adverse events and report them to drug safety agencies.

This case report highlights that new nonscarring alopecia after transplantation may indicate chronic graft-vs-host disease, with dermatologists playing a key role in diagnosis and treatment.

This study found that women with late onset acne have fewer comedones and acne lesions compared to those with early onset, despite no differences in P. acnes density or sebum secretion.

This study found that the SAAD-41 is a validated tool for assessing psychosocial outcomes in individuals with alopecia areata, showing strong correlations with established measures of quality of life and coping.

This study found that baricitinib, a Janus kinase inhibitor, was more effective than traditional treatments for severe alopecia areata, with higher rates of significant hair regrowth after 6 months, despite mild-to-moderate side effects and some instances of weight gain.

This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.

This review examines clinical data on the efficacy and safety of JAK inhibitors used for immune-mediated conditions beyond rheumatoid arthritis, highlighting their potential therapeutic roles in various inflammatory diseases.

This consensus document, developed by 23 dermatologists using a Delphi method, aims to guide the management of alopecia areata by providing structured recommendations for various stages of the condition, following expert opinion and scientific evidence.